BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
BeyondSpring (NASDAQ: BYSI), a global pharmaceutical company, announced management participation in the 4th Annual Evercore ISI HealthCONx Conference from November 30 to December 2, 2021. The Fireside Chat is scheduled for November 30 at 4:20 PM ET, with a webcast accessible via their website. BeyondSpring focuses on innovative cancer therapies, particularly its lead asset, plinabulin, which aims to prevent chemotherapy-induced neutropenia (CIN) and has received breakthrough designation in the U.S. and China. A significant PDUFA date of November 30, 2021, is noted for the U.S. approval process.
- None.
- None.
NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a Fireside Chat and host one-on-one investor meetings during the 4th Annual Evercore ISI HealthCONx Conference, taking place November 30-December 2, 2021. Details for the Fireside Chat can be found below:
| 4th Annual Evercore ISI HealthCONx Conference | |
| Date: | Tuesday, November 30, 2021 |
| Time: | 4:20pm ET |
| Webcast: | Click here |
A replay of the Fireside Chat will also be available on BeyondSpring’s website on the Events & Presentations page for 30 days following the conclusion of the conference.
About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset, plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), is being developed as a “pipeline in a drug” in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). It is filed for approval and has received breakthrough designation and Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a PDUFA date of November 30, 2021 in the U.S. In the DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, the plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com
Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com
FAQ
What is the date of BeyondSpring's Fireside Chat at the Evercore ISI HealthCONx Conference?
What time will BeyondSpring's Fireside Chat take place?
Where can I watch the BeyondSpring Fireside Chat?
What is the significance of the PDUFA date on November 30, 2021, for BeyondSpring?
What are the main focuses of BeyondSpring as a pharmaceutical company?
